Acrivon therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Watertown, mass., sept. 28, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced that the company approved a grant of equity awards under its 2023 inducement plan to two employees. the equity awards were granted in the form of restricted stock units (“rsus”) and stock options and have a grant date of september 26, 2023.
ACRV Ratings Summary
ACRV Quant Ranking